
INTerpath-001 and Personalized mRNA Vaccination in Resected High-Risk Melanoma
November 19, 2026
From the Co-Chairs, November 2026
November 19, 2026Now Enrolling: EA2251 for Patients With Advanced Biliary Tract Cancer
Young female doctor explaining medical information to senior man while holding clipboard, both sitting in clinical office setting, focused on discussion
EA2251 – Phase 2/3 Study of Ivonescimab Plus Chemotherapy for First-Line Treatment of Advanced Biliary Tract Cancer
Biliary tract cancer is a group of rare, aggressive gastrointestinal cancers that includes gallbladder cancer and several types of cholangiocarcinoma, or cancers that develop in the bile ducts. Because these cancers often cause few clear symptoms in their early stages, they are frequently diagnosed after the disease has already spread, when surgery to remove the cancer may no longer be an option.
For more than a decade, the standard first-line treatment for patients with advanced biliary tract cancer has included the chemotherapy drugs gemcitabine and cisplatin (GemCis). More recently, two large phase 3 clinical trials showed that adding immunotherapy—treatment that helps the immune system fight cancer—to GemCis can help patients live longer. These findings led to US Food and Drug Administration (FDA) approvals of durvalumab with GemCis in 2022 and pembrolizumab with GemCis in 2023, establishing both combinations as standard initial treatment options.
However, outcomes for patients with advanced biliary tract cancer remain poor, creating a need for more effective treatments. The EA2251 clinical trial was designed with this in mind. The randomized phase 2/3 study will evaluate whether adding the investigational drug ivonescimab to GemCis can improve survival compared with the current standard treatment of GemCis plus durvalumab or pembrolizumab.
Ivonescimab is a bispecific antibody, a type of drug designed to target two different proteins at the same time. It targets PD-1, a protein that cancer cells can use to evade the immune system, and VEGF, a protein involved in the development of blood vessels that tumors need to grow. By blocking both targets with a single drug, researchers hope to enhance the immune system’s ability to attack cancer while also limiting the tumor’s blood supply. Ivonescimab is not currently approved in the United States.
EA2251 follows promising results from HARMONi-GI1, a randomized phase 3 clinical trial conducted in China. In October 2026, the study sponsor reported positive results at the European Society for Medical Oncology (ESMO) 2026 Congress, showing that patients who received ivonescimab plus chemotherapy lived longer than those who received durvalumab plus chemotherapy. At 18 months, an estimated 44% of patients in the ivonescimab group were alive, compared with about 33% in the durvalumab group.
The study also reported improvements in progression-free survival, which measures how long patients live without their cancer worsening. At 9 months, an estimated 49% in the ivonescimab group were alive without their cancer worsening, compared with about 32% in the durvalumab group. Tumors shrank or disappeared on scans in about 54% of patients receiving ivonescimab compared with about 33% receiving durvalumab.
Serious medical events occurred in about 43% of patients receiving ivonescimab plus chemotherapy and 44% receiving durvalumab plus chemotherapy.
EA2251 will test whether similar benefits are seen in patients treated in the United States. Participants will be randomly assigned to receive either ivonescimab with GemCis or standard treatment with pembrolizumab or durvalumab plus GemCis.
The primary endpoint of the study is overall survival, or how long patients live after beginning treatment. Researchers will also compare the treatments based on progression-free survival, whether tumors shrink or remain stable, and how long any tumor shrinkage lasts. They will also compare the safety and side effects of these treatments.
The study is designed to generate evidence that could support a submission to the FDA seeking approval of ivonescimab plus chemotherapy for advanced biliary tract cancer.
Learn more about EA2251 at ecog-acrin.org.
The study chair for this trial is Deirdre J. Cohen, MD, MS (Icahn School of Medicine at Mount Sinai) and the co-chair is Dan Feng, MD, PhD (Icahn School of Medicine at Mount Sinai). The community co-chair is Steven J. Cohen, MD (Abington Hospital and Sidney Kimmel Comprehensive Cancer Center at Jefferson Health).
![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
